Jentadueto XR Gets FDA Approval

Jentadueto XR is now available as once-daily type 2 diabetes treatment

(RxWiki News) The US Food and Drug Administration has approved a once-daily form for Jentadueto.

Jentadueto XR, which contains the prescription drugs linagliptin and metformin, is used, in combination with diet and exercise, to treat type 2 diabetes.

Linagliptin belongs to a group of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. Metformin belongs to a group of drugs called biguanides. Together, these medications help control the amount of sugar in your blood.

In 2012, Jentadueto was approved as a twice-a-day dosing regimen. Now, Jentadueto XR offers patients a medication that only has to be taken once a day.

Jentadueto XR is available as an extended-release tablet and is to be taken once a day with a meal. Do not split, crush, dissolve or chew tablets. Swallow tablets whole.

This medication is not to be used by those with diabetic ketoacidosis or those diagnosed with type 1 diabetes.

Jentadueto XR carries a boxed warning regarding the risk of lactic acidosis, which is a buildup of lactic acid in the blood. Lactic acidosis is considered serious and must be treated in the hospital.

Jentadueto XR is marketed by Boehringer Ingelheim and Eli Lilly and Company.

Review Date: 
June 1, 2016